H.C. Wainwright analyst Debjit Chattopadhyay says Synthorx's (THOR) THOR-707 is "creeping up" on Nektar Therapeutics' (NKTR) bempeg. With THOR-707's profile, the analyst anticipates "profound changes to the pre- and post-treatment biomarkers" when compared to bempeg. In addition, THOR-809 is "poised to be the safer alternative" when compared to Nektar's NKTR-358, Chattopadhyay tells investors in a research note. THOR-809 is "bestowed with a superior ability" to expand CD4 and CD25 and :markedly less" impact on NK cell proliferation compared to NKTR-358, contends the analyst. Chattopadhyay keeps a Buy rating on Synthorx with a $30 price target.